- Home
- SENEA vs ARVN Comparison
SENEA vs ARVN Comparison
Compare SENEA & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SENEA | ARVN |
|---|---|---|
| Founded | 1949 | 2015 |
| Country | United States | United States |
| Employees | 6895 | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 949.4M | 781.0M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | SENEA | ARVN |
|---|---|---|
| Price | $143.16 | $12.14 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 21 |
| Target Price | N/A | ★ $15.71 |
| AVG Volume (30 Days) | 50.2K | ★ 734.1K |
| Earning Date | 01-01-0001 | 05-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 58.84 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $262,600,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $13.21 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $81.00 | $5.90 |
| 52 Week High | $148.97 | $14.22 |
Technical Indicators
Market Signals| Indicator | SENEA | ARVN |
|---|---|---|
| Relative Strength Index (RSI) | 65.78 | 40.19 |
| Support Level | $101.00 | $11.07 |
| Resistance Level | N/A | $12.62 |
| Average True Range (ATR) | 6.65 | 0.79 |
| MACD | 0.25 | -0.10 |
| Stochastic Oscillator | 71.59 | 35.94 |
Price Performance
Historical ComparisonAbout SENEA Seneca Foods Corp.
Seneca Foods Corp is a US-based company which acts as a provider of packaged fruits and vegetables. Its product offerings include canned, frozen, and bottled produce and snack chips. The company's segment includes Vegetable and Fruit/Snack. It generates maximum revenue from the Vegetable segment.
About ARVN Arvinas Inc.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.